Profound Medical Corp., or PROF, is a growing Canadian medical technology company that specializes in the development and marketing of customizable, incision-free therapies for the ablation of diseased tissue. PROF was established in 2008, and its share is currently listed on the Toronto Stock Exchange (TSX) and NASDAQ.
The company's key product is TULSA-PRO, an innovative medical device that combines real-time MRI technology with transurethral ultrasound therapy to provide clinicians with an accurate and precise tool to ablate prostate tissue. It is designed as an incision-free, radiation-free, and robot-assisted method of treating prostate healthcare issues, most notably prostate cancer. This revolutionary product drastically reduces recovery time and side-effects common with traditional treatments, thereby increasing patient comfort and wellbeing.
On the other side, PROF also developed Sonalleve, an incision-free therapeutic platform that combines real-time MR imaging and thermometry with thermal ultrasound to perform precise ablations of diseased tissue. Initially developed for ablation of uterine fibroids, Sonalleve has gained CE Marking for non-invasive treatment of palliative pain relief of bone metastases, osteoid osteoma, and essential tremor.
Profound Medical Corp. is devoted to improving patient outcomes and quality of life through innovation. The company conducts extensive clinical research and development in partnership with renowned medical institutions worldwide. Beyond research and development, PROF's growth strategy also includes forging strategic partnerships and acquisitions to ensure the continual expansion of its product portfolio and market reach.
In recent years, Profound Medical Corp has demonstrated consistent growth and success in the global medical market due to its unique and innovative approaches to disease treatment. By delivering heat non-invasively to destroy cancerous tissue, Profound is setting a new paradigm for the treatment of diseases like prostate cancer and uterine fibroids. Despite being relatively small, the company has become a leading medical technology firm within a highly competitive field, making significant strides in improving the overall care and prognosis for patients with critical health conditions.
With a mission of innovating the treatment landscape, high-quality products, and a track record of successful clinical results, Profound Medical Corp. is making impressive headway in advancing minimally invasive treatments in the medical field. With further development and research, the company is positioned to continue its impactful presence in the global healthcare market.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Profound Medical Corp. announced its participation in Lake Street Capital Markets' 10th Annual Best Ideas Growth Conference on September 10, 2026, in New York City. The company's management will hold one-on-one investor meetings at this event. Profound Medical is a commercial-stage medical device company specializing in innovative interventional MRI procedures, including its TULSA-PRO® platform for prostate ablation and Sonalleve® for various therapeutic applications.
Profound Medical Corp. (TSX:PRN) shares jumped 4.46% on August 26, 2026, driven by a surge in trading activity and investor interest. The specific catalyst for this sharp increase has not been independently confirmed through company disclosures. Profound Medical is a medical technology company specializing in MRI-guided, incision-free ablation therapy platforms, including its TULSA-PRO system for prostate tissue therapy.
Profound Medical (NASDAQ:PROF) exceeded quarterly earnings expectations, reporting an EPS of $0.26 against a projected loss of $0.22, with Q2 revenue rising 12% year-over-year. Despite some operational challenges like delayed shipments and uneven utilization, the company maintained its 2026 revenue target of $25 million and saw expanding reimbursement coverage for its TULSA procedure. The stock traded down slightly but analysts maintain a "Moderate Buy" rating with an average target price of $11.50.